Conclusion: Pharmacological elevation of
endocannabinoid levels may be a promising strategy to counteract intestinal
inflammation and colon
The two forms of IBD, ulcerative colitis
(UC) and Crohns disease (CD) have rapidly increased in the past years in
Western countries ranging at a prevalence of more than 200 cases per 100,000
chronic liver disease
Conclusion: The EC system is strongly
up-regulated during chronic liver diseases. Until now it has been implicated in
the pathogenesis of fatty
liver disease associated with
alcohol abuse, and
hepatitis C, in the
progression of fibrosis to cirrhosis, and in the development of portal
hypertension, hyperdynamic circulatory syndrome and its complications, and
cirrhotic cardiomyopathy. Furthermore, the EC system can participate in the
pathogenesis of acute liver injury by modulating the mechanisms responsible for
cell injury and inflammatory response. Thus, targeting the CB1 and CB2
receptors represents a potential therapeutic goal for the treatment of liver
Conclusion: Endocannabinoid-based therapies,
combining CB2 agonists and CB1 antagonists may open novel therapeutic
perspectives for the treatment of chronic liver diseases.
Conclusion: CB1 receptors have been
implicated in the pathogenesis of several lesions such as liver fibrogenesis,
alcoholic and metabolic steatosis, or circulatory failure associated with
cirrhosis. In contrast, stimulation of hepatic CB2 receptors is emerging as an
overall protective pathway with antifibrogenic properties and beneficial
effects on liver inflammation, alcoholic fatty liver and hepatocyte survival
Conclusion: CB2 receptors reduce liver
injury and promote liver regeneration following acute insult, via distinct
paracrine mechanisms involving hepatic myofibroblasts.
Conclusion: Our study shows that CB1
receptor antagonists hold promise for the treatment of liver fibrosis.
Conclusion: CBD can alleviate lipid
accumulation in both an in vitro HepG2 cell model and an in vivo binge alcohol
treatment model by multiple mechanisms.
Conclusion: These findings demonstrate that
CB2 receptors display beneficial effects on alcohol-induced inflammation by
regulating M1/M2 balance in Kupffer cells, thereby reducing hepatocyte
steatosis via paracrine interactions between Kupffer cells and hepatocytes.
Conclusion: Our results suggest that THCV
and CBD might be used as new therapeutic agents for the pharmacological
treatment of obesity- and metabolic syndrome-related
Conclusion: Cannabinoids have great promise
as treatments for nausea and that their anti-nausea effects may be mediated by
the interoceptive insular cortex.
Conclusion: This model may be a useful tool
for elucidating the neurobiology of nausea and the role that the
endocannabinoid system plays in the regulation of this distressing
Conclusion: Future efforts aimed at
developing new endocannabinoid-based anti-nausea and anti-emetic therapies are
Conclusion: Our data suggest a possible
implication of the endocannabinoid system in the physiology and development of
the human kidney.
Conclusion: CB1 has a major role in the
activation of myofibroblasts and may be a new target for treating chronic
Cannabidiol, a safe and non-psychotropic
ingredient of marijuana, exerts pharmacological effects (e.g., antioxidant) and
mechanisms (e.g., inhibition of endocannabinoids enzymatic degradation)
potentially beneficial for the inflamed gut.
Conclusion: A short course (8 weeks) of
THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of
11 patients with active Crohn's disease, compared with
placebo, without side